S
Spruce Biosciences Inc D
D
SPRB
41.730
USD
2.79
(7.16%)
Pre Open·40.230USD-1.500(-3.59%)
Last updated: · Delayed 15 min
Volume
2
EPS
-26
Div Yield
-
P/E
-1
Market Cap
119,932,562
Title: Spruce Biosciences Inc
Sector: Healthcare
Industry: Biotechnology
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.